For an established patient visit with an established diagnosis, along with a new diagnosis, the visit should be coded as 99214 and billed under the PA’s national provider identification (NPI) number
ACR/ARHP Annual Meeting 2012: How Rheumatologists Can Negotiate Better Contracts with Payers
Improving contracts with payers can earn rheumatologists more money, with no added costs in staffing or equipment
ACR/ARHP Annual Meeting 2012: Understanding Pain Signals May Pave Path to More Effective Therapies
The ability to differentiate the types of pain affiliated with rheumatic diseases can help rheumatologists better diagnose and treat patients
ACR/ARHP Annual Meeting 2012: Rheumatologists Take Proactive Approach in Talking with Teen Patients about Risky Behavior
With teenaged juvenile arthritis patients, it’s important for rheumatologists to engage in conversations about how drugs, tobacco, alcohol, and sex will affect them
ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines
People with rheumatic diseases can be considered to receive flu and pneumococcal vaccines even if they’re on immunosuppressive drugs
ACR/ARHP Annual Meeting 2012: Will Novel Strategies Lead to Breakthroughs in Treating Osteoarthritis?
ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis
Novel strategies for treating osteoarthritis aim to relieve pain, rebuild or replenish deteriorated cartilage and bone, or to replace the joint through surgery
Letter: Consider the Bent Fork
As rheumatologists, when people ask us about wearing the bent fork lapel pin, we have the opportunity to educate the public about the Simple Tasks Campaign and the value of rheumatology
Letter: Praise for SAPHO Syndrome Article
After reading your article on SAPHO, I may get a better treatment plan for my patient; thanks for drawing the attention of American College of Rheumatology members to an obscure condition that can vex patients and clinicians
ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis
Rituximab established as the drug of choice in patients with severe disease relapse, though cyclophosphamide may still play an important role for some patients, say rheumatologists
- « Previous Page
- 1
- …
- 655
- 656
- 657
- 658
- 659
- …
- 807
- Next Page »